title: [Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC): evaluation, prevention and policies to avoid occupational exposure for operating room personnel].
abstract: To develop a treatment strategy for peritoneal carcinomatosis using a combination of extended peritoneal resections, local destructive procedures and hyperthermic intraperitoneal chemotherapy creates great concern between healthcare workers involved in these procedures. New professional risks exist: risk of exposure to cytotoxic drugs, environmental risks (inhalation of smoke, aerosolization of chemotherapy agents). Information, education and training of healthcare workers is mandatory in order to ensure proper evaluation, prevention, and management of professional exposure risks in coordination with the occupational health office.
authors.affiliation: IBODE, Bloc Opératoire, Institut Claudius-Regaud, Centre de Recherche et de Lutte Contre le Cancer, 20-24 Rue du Pont-Saint-Pierre, 31052 Toulouse, France.
authors.forename: L
authors.initials: L
authors.lastname: Simon
authors.forename: M-C
authors.initials: MC
authors.lastname: Halilou
authors.forename: L
authors.initials: L
authors.lastname: Gladieff
authors.forename: M
authors.initials: M
authors.lastname: Gadiou
authors.forename: F
authors.initials: F
authors.lastname: Herin
authors.forename: I
authors.initials: I
authors.lastname: Hennebelle
authors.forename: E
authors.initials: E
authors.lastname: Chatelut
authors.forename: G
authors.initials: G
authors.lastname: Ferron
mesh_terms: D000395:Air Pollutants, Occupational / Q000633:toxicity; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D002277:Carcinoma / Q000188:drug therapy* / Q000601:surgery; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000009:adverse effects* / Q000193:education / Q000379:methods; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003666:Decontamination / Q000379:methods; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004339:Drug Compounding / Q000009:adverse effects; D004598:Electrosurgery / Q000009:adverse effects; D006358:Hot Temperature; D006801:Humans; D000077146:Irinotecan; D016685:Mitomycin / Q000008:administration & dosage / Q000009:adverse effects; D016273:Occupational Exposure / Q000009:adverse effects / Q000517:prevention & control*; D009873:Operating Rooms; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000601:surgery; D011481:Protective Clothing; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects; D012906:Smoke / Q000009:adverse effects; D014691:Ventilation / Q000379:methods
chemical_list: D000395:Air Pollutants, Occupational; D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D011725:Pyridines; D012906:Smoke; C431073:oxiplatin; D016685:Mitomycin; D000077146:Irinotecan; D004317:Doxorubicin; D002945:Cisplatin; D002166:Camptothecin